Lanean...

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

BACKGROUND: Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that contains the full-length spike glycoprotein of the prototype strain plus Matrix-M adjuvant, showed that the...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:N Engl J Med
Egile Nagusiak: Heath, Paul T., Galiza, Eva P., Baxter, David N., Boffito, Marta, Browne, Duncan, Burns, Fiona, Chadwick, David R., Clark, Rebecca, Cosgrove, Catherine, Galloway, James, Goodman, Anna L., Heer, Amardeep, Higham, Andrew, Iyengar, Shalini, Jamal, Arham, Jeanes, Christopher, Kalra, Philip A., Kyriakidou, Christina, McAuley, Daniel F., Meyrick, Agnieszka, Minassian, Angela M., Minton, Jane, Moore, Patrick, Munsoor, Imrozia, Nicholls, Helen, Osanlou, Orod, Packham, Jonathan, Pretswell, Carol H., San Francisco Ramos, Alberto, Saralaya, Dinesh, Sheridan, Ray P., Smith, Richard, Soiza, Roy L., Swift, Pauline A., Thomson, Emma C., Turner, Jeremy, Viljoen, Marianne E., Albert, Gary, Cho, Iksung, Dubovsky, Filip, Glenn, Greg, Rivers, Joy, Robertson, Andreana, Smith, Kathy, Toback, Seth
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Massachusetts Medical Society 2021
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8262625/
https://ncbi.nlm.nih.gov/pubmed/34192426
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2107659
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!